This promotional website is
intended for UK healthcare professionals only
This promotional website is intended for UK healthcare professionals only
ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens1
ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy1
Enhertu has a Conditional Marketing Authorisation
If you have any questions about ENHERTU or would like to speak to your local representative, please complete the form below. Fields marked with * are mandatory.
Note: Your personal details will not be used for any promotional purposes unless you choose to opt in to promotional content by checking the box below. More details can be found in the Daiichi Sankyo Privacy Policy and AstraZeneca Privacy Policy.
UK/ADC/01/25/0009 | April 2025
